| Identification | Back Directory | [Name]
Carbamic acid, N-methyl-N-[2-(methylamino)ethyl]-, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl ester, 2,2,2-trifluoroacetate (1:1) | [CAS]
1224601-17-5 | [Synonyms]
(S)-2-((((4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl)oxy)carbonyl)(methyl)amino)-N-methylethan-1-aminium
Carbamic acid, N-methyl-N-[2-(methylamino)ethyl]-, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl ester, 2,2,2-trifluoroacetate (1:1) | [Molecular Formula]
C27H30N4O6.C2HF3O2 | [MOL File]
1224601-17-5.mol | [Molecular Weight]
620.57 |
| Hazard Information | Back Directory | [Uses]
SN-38-CO-DMEDA TFA is the intermediate product for synthesizing antibody-conjugated drug LND1035[1]. | [References]
[1] Xu Zhe, et al. Method for preparation of antibody-conjugated drug LND1035. China, CN113583086 A. 2021-11-02. |
|
|